Pfizer diabetes program improves health outcome

Share this article:
Pfizer Health Solutions is taking its diabetes patient education program Amigos en Salud/ Friends in Health national after a four-city pilot showed significant improvements in health outcomes among diabetes patients.

The program, aimed at helping African American and Hispanic patients self-manage their diabetes, was designed for implementation by community health workers in conjunction with clinics or hospitals. Materials will be made available on the program's Web site, amigosensalud.com, for download by community health centers and publicized through conventions, word-of-mouth and via e-mail.

The pilots found statistically significant improvements not only in diabetes management among patients, but also in cholesterol levels, depression, cardiovascular health and other co-morbid conditions.

“We saw this as an opportunity to run pilots so that we could show that, in fact, they're an excellent way to improve healthcare at a low cost rather than using health professionals in areas where access is a problem,” said Eileen Crowley, senior project manager at Pfizer Health Solutions, a Pfizer subsidiary.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...